Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Tinib Antineoplastic drugs >  Mubritinib

Mubritinib

Basic information Safety Supplier Related

Mubritinib Basic information

Product Name:
Mubritinib
Synonyms:
  • MUBRITINIB
  • 1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
  • TAK 165
  • Mubritinib(TAK 165)
  • CS-522
  • TAK165;TAK-165
  • (E)-1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
  • 1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole Mubritinib (TAK 165)
CAS:
366017-09-6
MF:
C25H23F3N4O2
MW:
468.47
Product Categories:
  • Inhibitors
Mol File:
366017-09-6.mol
More
Less

Mubritinib Chemical Properties

Melting point:
158.0 to 162.0 °C
Boiling point:
620.9±65.0 °C(Predicted)
Density 
1.25±0.1 g/cm3(Predicted)
storage temp. 
Store at +4°C
solubility 
DMSO : 50 mg/mL (106.73 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
pka
1.45±0.10(Predicted)
form 
powder to crystal
color 
White to Gray to Brown
InChI
InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
InChIKey
ZTFBIUXIQYRUNT-MDWZMJQESA-N
SMILES
N1(CCCCC2=CC=C(OCC3=COC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=N3)C=C2)C=CN=N1
More
Less

Safety Information

HS Code 
2934.99.4400
More
Less

Mubritinib Usage And Synthesis

Uses

Treatment of cancer.

Uses

Mubritinib is used in selective targeting of CTNNB1-, KRAS-or MYC-driven human cancer cell growth by combinations of existing drugs

Biological Activity

Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC 50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC 50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo .

in vivo

In the xenograft model, treatment with Mubritinib (TAK-165) significantly inhibits growth of UMUC-3, ACHN, and LN-REC4. The antitumor effect after 14 days treatment are 22.9%, 26.0%, and 26.5% in UMUC3, ACHN and LN-REC4, respectively[1].

IC 50

HER2: 6 nM (IC50)

storage

Store at +4°C

MubritinibSupplier

Guangzhou Tomums Life Science Co., Ltd. Gold
Tel
020-31155029 18902330969
Email
sales@tomums.cn
Taizhou Chuanxu Pharmaceutical Technology Co., Ltd. Gold
Tel
13000000000
Email
974144639@qq.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com